Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) has been the subject of intensive investigations in laboratory animals during the last 2 decades. Toxicity studies have been conducted in several species of rodents and include several carcinogenicity studies as well as numerous mechanistic studies initiated to elucidate dioxin's mode of action, as both a carcinogen and a toxicant. Hepatotoxicity is a primary effect of dioxin. There has been an increase in hepatocellular tumors reported in both rats and mice exposed to dioxin. In addition to neoplastic changes, dioxin causes a spectrum of toxic changes in the liver. Additional neoplastic changes include subcutaneous fibrosarcomas and thyroid follicular cell tumors in both rats and mice and histiocytic sarcomas in mice. Dioxin causes devlopmental effects in the palate and kidney of mice. Changes in the female reproductive tract include ovarian atrophy, sertoliform hyperplasia, and Sertoli cell tumors. Dosing in utero results in gross malformations of the external genetalia. The effects of dioxin on the rodent model of endometriosis are described. In males, there are lowered sperm counts in the epididymis and minor testicular effects following gestational administration of dioxin. Both estrogenic and antiestrogenic-like effects have been ascribed to dioxin in laboratory animals; these activities are the result of dioxin-specific pathways resulting in the same end points as classic reproductive toxicants.
2,3,7,8-Tetrachlorodibenzo p-dioxin (TCDD, dioxin) has been described as the most toxic man-made chemical. TCDD is released into the environment as a contaminant of herbicides or as a byproduct of manufacturing processing. A spectrum of effects and lesions have been reported in humans or have been induced in experimental animals. This paper will review some of the major lesions in several species of laboratory animals.
EFFECTS OF TCDD IN PEOPLE
A number of lesions have been recorded in people following exposure to TCDD. These include chloracne, soft tissue sarcomas, non-Hodgkins lymphomas, and hepatic effects. Chloracne is considered to be pathognomonic for exposure to high levels of dioxin or related halogenated aromatic compounds. It consists of a persistent acneform condition characterized by comedones and keratin cysts that initially occur on the malar ridge and behind the ears. Inflammatory pustules, hyperpigmentation, abscesses, and large cysts may occur in severe cases. These lesions may persist for months or even years after exposure. Although chloracne is specific for dioxin exposure, it is not extremely sensitive, because some patients with large exposures never develop chloracne (18) .
Over the past several decades, a number of epidemiologic studies have been conducted examining the cancer rates in several populations following exposure to dioxins. These populations included workers during the production of chemicals contaminated with TCDD, agricultural workers exposed to contaminated herbicides, pulp and paper mill workers, Vietnam veterans exposed to Agent Orange, a defoliant contaminated with dioxin, and residents of Seveso, Italy, following a chemical accident in 1976 (7, 15, 18) . Exposure-related increases for the following neoplasms were suggested in 1 or more of these studies: soft tissue sarcomas, non-Hodgkins lymphomas, liver, lung, and stomach cancers. For many of these tumors, the evidence is weak at best and is often confounded by other studies. There have, however, been 3 recent mortality studies involving occupational exposure that were validated by serum TCDD levels in a subset of the exposed cohort, which demonstrated an increased risk for all cancer types after dioxin exposure (1) .
The liver is a target for TCDD toxicity in humans. Mild hepatic enlargement and elevation of hepatic enzymes including gamma glutamyltransferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) follow exposure. Although hepatocellular neoplasms have been reported as an effect of TCDD exposure in people, the evidence for this is weak.
Other effects reported in people include nervous system signs (peripheral neuropathy, fatigue, anxiety, and decreased libido), an increased incidence of diabetes, hypercholesterolemia or hypertriglyceridemia associated with weight loss, altered levels of reproductive hormones, and possible developmental effects.
EFFECTS OF TCDD IN LABORATORY ANIMALS
The effects of TCDD and related compounds have been studied extensively in laboratory animals for the last several decades. A variety of effects have been reported to be associated with the administration of TCDD via several different routes of administration (gavage, feed, and dermal application). These include hyperplasia of epithelial tissues in several organs (liver, bile duct, gastric mucosa, and urinary bladder), dermal lesions resembling chloracne in humans, a wasting syndrome characterized by delayed lethality and a progressive weight loss after exposure, developmental and reproductive effects, immunotoxic effects, and carcinogenic effects (22) . It is in the area of carcinogenic effects that a difference is seen between studies in humans (epidemiologic studies) and laboratory animals (experimental studies); dioxin has been proven to be carcinogenic at several sites in 4 species of laboratory animals. At least 18 carcinogenicity studies with TCDD have been completed and have shown that dioxin causes hepatocellular neoplasms in rats and mice, subcutaneous fibrosarcomas in mice, squamous cell carcinomas in the tongue, hard palate and lung in rats, histiocytic sarcomas in mice, and squamous cell carcinomas in the facial skin of golden hamsters as well as tumors in multiple sites and organs in Japanese Medaka (10, 11, 16) .
CARCINOGENICITY STUDIES
One of the first studies to show that dioxin was a carcinogen was conducted by the Dow Chemical Company and was reported in 1978 (14) . The study was conducted in Sprague-Dawley rats at doses up to 0.1 [ig TCDD/kg/ day. The compound was administered in the diet of the animals for 2 yr. Treatment-related effects included an increase in mortality in treated rats, decreased body weight gain, changes in hematology and clinical chemistry parameters, and a number of morphologic changes. Females given 0.1 pLg TCDD/kg/day had increased mortality during the study, while the effect on early mortality in males was questionable. Mean body weights of both sexes were reduced when compared to controls for most of the study. A number of hematologic parameters (packed cell volume, hemoglobin, and total red blood cell counts) were decreased, while reticulocyte counts were slightly elevated at the end of the study. Clinical chemistry and urinalysis end points were affected in female rats only. Urinary porphoryins and 8-aminolevulinic acid excretion were increased at the high dose only. Serum alkaline phosphatase, AST, and ALT were all increased at the time of the terminal necropsy.
The liver was the primary target organ in the Dow study. Toxic hepatitis, which was more extensive in females than in males, consisted of cytomegaly, distortion of the lobular pattern with resultant atrophy of hepatic cords, cytoplasmic vacuolation, fatty infiltration, altered tinctorial qualities with increased basophilia, hepatic ne-crosis, and inflammation and areas of focal alteration. These changes were accompanied by increased aggregates of pigment in Kupffer cells and bile duct hyperplasia with increased fibrosis and periportal inflammation.
An increase in hepatocellular tumors-both adenomas and carcinomas-was present in high-dose female rats. Since the study was reported, there have been several reviews and pathology working groups conducted of the liver tumors (12) . Criteria and incidence numbers have varied, but the consensus remains that there is at least an increase in hepatocellular carcinomas in female rats treated with TCDD for 2 yr.
In addition to the liver tumors, there was an increase in squamous cell carcinomas of the tongue, hard palate, nasal turbinates, and lung in both sexes. This effect has not been reported in subsequent studies, and it has been suggested that the dietary route of administration allowed either longer direct contact between the compound and the affected organs or the accidental aspiration of TCDDtreated food (13) .
While there was an increase in liver tumors and squamous cell carcinomas, there was a decrease in the incidence of mammary tumors in treated rats at the end of the study. This decrease may have been due to the decreased body weight of the animals at the end of the study. A number of other morphologic changes were reported in the Dow study along with the increase in hepatic carcinogenesis. The immune system appeared to be affected because there was both thymic and splenic atrophy reported in female rats. In the lung, in addition to the squamous tumors, there was an increase in alveolar epithelial hyperplasia in both sexes. The high-dose females also had a decreased incidence of several age-related changes, including cystic endometrial hyperplasia, while the males showed a decrease in the incidence of chronic renal disease.
The Dow study remains important because most of both the neoplastic and nonneoplastic changes have been repeated in the carcinogenicity studies that followed. Although the increase in squamous tumors associated with exposure to TCDD have not occurred in other chronic studies, the increase in hepatocellular tumors has occurred in several other long-term studies. The National Toxicology Program (NTP) has conducted several carcinogenicity studies with TCDD. In a multispecies report published in 1982 (20) , TCDD was administered twice a week by gavage at doses of up to 0.5 pLg TCDD/kg/wk to Osbome-Mendel rats of both sexes and male B6C3F, mice and up to 2.0 pLg TCDD/kg/wk for female mice.
In the rats, there were significant increases in neoplasia in the liver and thyroid. Both hepatocellular adenomas ( Fig. 1 ) and carcinomas (Fig. 2 ) were increased in highdose female rats. There was an increase in the incidence of follicular cell adenomas of the thyroid (Fig. 3 ) in treated male rats. The incidence of subcutaneous fibrosarcomas ( Fig. 4 ) was increased in female rats.
Toxic hepatitis was commonly found in high-dose rats of either sex. This change was characterized by lipidosis and hydropic degeneration of the cytoplasm of hepatocytes ( Original magnification, x5. fibrosis were also common findings ( Fig. 6 ). Eosinophilic and clear cell foci of cellular alteration were seen in the liver of many high-dose rats.
In the B6C3F, mice, there was an increase in tumors of the liver, thyroid, hematopoietic system and subcutaneous tissue. Hepatocellular adenomas (Fig. 7 ) and carcinomas ( Fig. 8 ) were significantly increased in high-dose mice of both sexes. Follicular adenomas of the thyroid were increased in high-dose female mice. There was an increase in the incidence of histiocytic sarcoma and subcutaneous fibrosarcomas in females only.
In the liver, there was a dose-related increase in toxic hepatic lesions. These lesions were characterized by cytomegaly, intranuclear inclusions, lipidosis, bile duct hyperplasia, and peribiliary fibrosis. Pigment was frequently present in Kupffer cells.
The NTP also conducted a dermal study in Swiss-Webster mice. In this study, also reported in 1982 (21) , dermal application of either TCDD alone or TCDD following initiation by 7, 12-dimethylbenzanthracene (DMBA) resulted in an increased incidence of fibrosarcomas ( Fig. 9 ) at the site of application in female mice only. The TCDD was administered 3 times a week at doses of 0.001 [Lg (males) or 0.005 jjbg/application (females). There was no 
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Original magnification, X6.6. difference seen between animals pretreated with DMBA and those treated with TCDD alone. Although the incidence of fibrosarcomas was elevated in treated male mice, the difference was not significant. A few toxic lesions were present in the liver and might have been related to TCDD treatment, but no toxic or inflammatory lesions were present in the skin at the site of application.
INITIATION-PROMOTION STUDIES
While carcinogenicity studies have shown that TCDD is a complete, nongenotoxic carcinogen by itself, a large number of recent experimental studies have focused on the properties of dioxin as a promoter in the 2-stage carcinogenesis model (17) . Dioxin is a potent promoter of hepatocarcinogenesis following initiation by compounds such as diethylnitrosamine (DEN) . In a recent initiationpromotion study conducted for the National Institute of Environmental Health Sciences, Sprague-Dawley rats were given a single necrogenic dose of DEN (175 mg/kg), followed by TCDD (dose equivalent to 125 ng/kg/day) for up to 60 wk. Some groups were allowed to recover after the period of TCDD promotion in order to examine the reversibility of some of the changes.
The nonneoplastic effects in the liver were similar to those seen in the rodent carcinogenicity studies-the ma- Original magnification, X66. jor nonneoplastic effect consisted of a toxic hepatitis, characterized by fatty change, bile duct hyperplasia, cystic degeneration, peribiliary fibrosis, pigment in Kupffer cells, oval cell proliferation, and biliary cysts. The effects were generally more severe than those seen after the administration of TCDD alone. There were many areas where the overall effect of the toxic changes were difficult to distinguish from foci of cellular alteration.
The neoplastic effects included hepatocellular adenomas and carcinomas along with cholangiomas and cholangiocarcinomas. Because the incidence of biliary cysts was much higher in animals treated with TCDD than those that had only been initiated with DEN, it was concluded that these cysts were related to treatment with TCDD. Similarly, cholangiomas and cholangiocarcinomas were only present in animals that had received both regimens, suggesting that these tumors, which were not recorded in the TCDD carcinogenicity studies, were related to the administration of TCDD acting as a promoter.
The majority of the foci of cellular alteration present in the study were eosinophilic or basophilic. As already mentioned, many of the eosinophilic foci were difficult to distinguish from less discrete areas of hepatocellular hypertrophy due to dioxin toxicity. In the 2-stage hepatocarcinogenesis model, the first morphologic indication of a chemically induced carcinogenic process is the appearance of putatively preneoplastic foci of cellular alteration in the liver (17) . A number of different markers have been used to identify those foci. It has been demonstrated that TCDD modifies the number and size of focal lesions in the livers of female rats (23) .
Administration of bromodeoxyuridine via an osmotic minipump labels cells in the S phase. However, in TCDD-treated livers, this marker does not distinguish the preneoplastic foci from the surrounding liver. In rats, enzyme histochemical staining for the placental form of glutathione S-transferase (PGST+) is considered a reliable marker for preneoplastic lesions in the liver. An increased number of PGST+ foci in initiation-promotion models can be considered a reflection of tumor promotion, because hepatic tumor promoters are known to accelerate the appearance of foci of cellular alteration and are able to increase the number and/or size of foci at a given time interval. One hypothesis on the mechanism of how TCDD results in the increased production of PGST+ cells is based on the observation that TCDD alters the production of cytochrome P-450 1 A2 (CYPIA2), which Frog. 8.-Hepatocellular carcinoma. Within the mass, neoplastic cells form thick trabeculae which are many cells thick (arrows). Liver, female B6C3F, mouse. H&E.
Original magnification, X66. results in an increase in the metabolism of estrogens to catechol estrogens. Further activation of these catechol estrogens can lead to cell damage and eventual mutations (16) . Further evidence for the importance of estrogen in TCDD toxicity in the liver comes from the fact that TCDD is not carcinogenic to the liver in ovariectomized rats (25) . DEN and TCDD have been shown to interact in the 2-stage carcinogenesis model, producing greater initiation than either one would produce alone. TCDD has been termed an activator in this model to indicate that it may cause increased initiation, and possibly promotion, via indirect mechanisms not related directly to the genotoxic activity of a compound or its metabolites (23) .
DEVELOPMENTAL EFFECTS OF TCDD
TCDD has been shown to be an important developmental toxin in several species of laboratory animals.
Most if not all of the activities of TCDD involve a cytosolic protein, the Ah receptor. This receptor functions as a ligand-activated transcriptional enhancer (1) . The TCDD-receptor complex binds to specific sequences in the regulatory regions of DNA, causing alterations in gene expression. This type of receptor-mediated mechanism is characteristic of all hormones, growth factors, and cytokines. As such, it is useful to consider dioxin acting via the Ah receptor as an environmental hormone. Dioxin can be a potent mimetic, blocker, or modulator, depending on the species, the organ, and the dose. Dioxin may have antiestrogenic effects or estrogenic effects. Because it acts through the Ah receptor and not the estrogen receptor, it is surmised that it utilizes different pathways to effect changes in the same sets of target tissues. Structural defects have been produced in the mice and rats by exposing pregnant females to TCDD during gestation. The best described malformation is the cleft palate (2, 3) . Di-oxin causes cleft palate by altering the proliferation and differentiation of medial epithelial cells of the developing palate. These abnormalities are brought about by changes in the balance of various growth factors and their receptors in the developing palate. Dioxin treatment results in a failure of programmed cell death of epithelial cells in the developing palate. These effects are mediated through the Ah receptor; exposure to TCDD results in altered expression of the Ah receptor in both the epithelium and the mesenchyme.
Another developmental effect of exposure to TCDD is hydronephrosis (2, 3) . This deformation is due to hyperplasia of the epithelium of the ureters that progresses to blockage of the lumen. Mechanical destruction of renal parenchyma results from pressure from urine produced by the developing fetus. TCDD treatment results in elevated levels of epithelial growth factor, modulated by the Ah receptor, in both the palate and the ureter.
EFFECTS OF TCDD ON THE FEMALE REPRODUCTIVE SYSTEM
Dioxin has been shown experimentally to have a range of effects on several organs in the female reproductive system. In the initiation-promotion study cited earlier, morphologic changes were present in both the uterus and the ovary. Many of the endometrial glands in animals treated with TCDD for 60 wk had squamous metaplasia of the glandular epithelium. In the ovary of rats initiated with DEN and promoted with TCDD, changes included ovarian atrophy and inactivity, sertoliform hyperplasia, and Sertoli cell tumors, both benign and malignant. Sertoliform hyperplasia did not appear to precede or progress to the Sertoli cell tumors. In this study, there was also a reduction in the incidence of mammary tumors (and body weight) similar to that seen in several of the carcinogenesis studies.
A number of studies conducted at the Environmental Protection Agency (EPA) (9) have examined the longterm effects of dioxin on the reproductive tracts of fetuses exposed to dioxin on specific days of gestation. The dosages in these studies were too low to cause toxicity in the dams but had profound effects on the pups. Ovarian atrophy and sertoliform hyperplasia similar to that seen in the adult animals exposed to dioxin were present in Long-Evans rats exposed on gestation day (GD) 15 and sacrificed at approximately 1.5 yr of age. Ovarian atrophy was also present in hamsters exposed on GD 11, which were sacrificed approximately 1 yr later. In rats, changes in the uterus included squamous metaplasia of uterine glands (Fig. 10 ) as well as a squamous cell carcinoma of the uterus, a relatively rare tumor in untreated control Fischer-344 rats. Several of the studies (both hamster and rat) had autolytic, macerated fetuses retained in the uterus. Fetal death and retention have been described as a result of TCDD exposure (4) . In females exposed to TCDD in utero, there are often gross morphologic changes present. In Long-Evans rats, there was malformation of the external genitalia after exposure to TCDD on GD 8 or 15. In unexposed rats, the urethral opening is at the end of the prepuce. In the treated females, the phallus was partially or completely cleft Original magnification, X66. and the urethral opening was at the upper end of the cleft area. These types of malformations of the external genitalia are also produced by gestational exposure to estrogens such as diethylstilbestrol and estrogenic fungicides. TCDD has been shown to be more effective in inducing malformations in female offspring than any of the potent estrogens (9) . In addition, many of the exposed rats had a persistent vaginal thread present. This thread of tissue represents an inhibition of estrogen-mediated cell death of the vaginal membrane at puberty (9) . Because TCDD does not produce overt malformations of the genitalia in male progeny, it has been suggested that the female fetus may be more sensitive to TCDD than the male.
The effects of TCDD on the female reproductive tract have also been investigated using the recently developed rodent model of endometriosis (5, 6) . In this model, a 1-cm length of rat uterus or 1 entire mouse uterine horn is opened longitudinally and cut into either 6 (rat) or 3 (mouse) pieces of approximately 2-3 mm2 each. All the uterine squares are then sutured to vessels of the mesentery in the animals from which the uterine tissue originated.
In women, the ectopic endometrial tissue of endometriosis may appear as nonpigmented clear vesicles, with Original magnification, X40.
white plaques and reddish petechiae ranging from several millimeters to 2 cm in diameter. These vesicles may be superficial or invasive, and both inflammation and adhesions are common. In the rodent model, the transplanted endometriotic sites form clear, fluid-filled vesicles that apparently develop from distended uterine glands. In a recent set of experiments utilizing the rodent endometriosis model, rats and mice were treated with up to 10 pLg/kg TCDD both before and after surgery for up to 12 wk. Exposure to TCDD caused an increase in the diameter of the endometriotic sites in rats. Histologic changes in the endometriotic sites in the rat included fibrosis, hemorrhage, and inflammatory cells [mostly polymorphonuclear neutrophilic leukocytes (PMNs)] both in the wall of the site and in the lumen (Fig. 11 ). In mice, the endometriotic sites were significantly enlarged after exposure to TCDD. Histologic changes in mice included fibrosis in the wall of the endometriotic site and PMNs in the lumen (Fig. 12 ). Ovarian changes were also present in the rats treated with TCDD with the rodent endometriosis model. There was ovarian atrophy similar to that seen in the long-term exposure (60-wk study) and the in utero exposure. Ovulatory arrest was suggested by the lack of corpora luteum 
EFFECTS OF TCDD ON THE MALE REPRODUCTIVE SYSTEM
In male offspring of dams exposed during pregnancy, the morphologic changes were generally less severe than those present in exposed females. There was permanent reduction in epididymal sperm counts as well as a reduction in the size of accessory sex glands in both rats and hamsters. The effects in the testes were less pronounced but included occasional sperm granulomas and degeneration of seminiferous tubules (Fig. 15 ). The spermatid numbers in the testes were not affected by dioxin (8) . It has been suggested that TCDD exposure during development alters epididymal/urogenital differentiation in the fetal/neonatal male rat and hamster such that epididymal sperm reserves are permanently reduced, an effect that contributes to a reduction in ejaculated sperm numbers. In addition to the epididymal changes, there was an increase in severity of chronic nephropathy in treated hamsters, suggesting that the urogenital system is a target for the developmental effects of TCDD in hamsters, as previously shown in mice in the development of hydronephrosis (2, 3) . While some studies have shown that TCDD causes decreases in the plasma concentration of androgens as well as a reduction in the weight of accessory sex organs (19) and may thus be considered an antiandrogen (24) , others report normal levels of testosterone in male offspring with reduced epididymal sperm counts (8) . SUMMARY Exposure to dioxin causes a wide variety of effects in several species of laboratory animals. Given alone, TCDD causes hepatocellular neoplasia in female rats and mice of both sexes. It also causes subcutaneous fibrosarcomas, at the site of application in dermal studies as well as in gavage studies in both species. In initiation-promotion studies, dioxin has been shown to be a potent promoter of hepatocarcinogenesis.
The liver is also the primary target organ for the nonneoplastic effects of TCDD. Chronic administration caus- Original magnification, X50. es toxic hepatitis in both mice and rats, characterized by fatty change, hepatocellular degeneration, bile duct hyperplasia, peribiliary fibrosis, and accumulation of pigment in Kupffer cells. There is also an increase in several types of foci of cellular alteration in the liver. Developmental effects of TCDD administration include cleft palate and hydronephrosis. A variety of effects are seen in both the male and female reproductive tracts. In the female reproductive tract, these include external malformations, ovarian neoplasia and metaplastic changes in the uterus. Changes in the male reproductive tract include reductions in sperm in the epididymis and a low incidence of testicular degeneration.
Experimental evidence suggests that TCDD can act in both an estrogenic and antiestrogenic manner, depending on the dose, species, and organ system involved. Because dioxin exerts its modulatory actions through the Ah receptor, it appears that the estrogenic and antiestrogenic activities are the result of dioxin-specific pathways resulting in the same end points as classic reproductive toxicants.
